Skip to main content
. Author manuscript; available in PMC: 2023 Jun 6.
Published in final edited form as: Clin Cancer Res. 2020 Oct 7;27(1):288–300. doi: 10.1158/1078-0432.CCR-20-3237

Figure 1. Clinical outcomes in patients randomised to FUFA or to OxFU in FOCUS trial by DDIR score.

Figure 1

A) Progression free survival (to 15 months) B) Overall response rate (ORR) C. Pathological response assessment in resected primary following 6 weeks oxaliplatin based chemotherapy in FOxTROT trial by DDIR score.